Adial Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADIL research report →
Range $6 – $11
Price Chart
About the company
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder.
- CEO
- Cary John Claiborne
- IPO
- 2018
- Employees
- 5
- HQ
- Glen Allen, VA, US
Get TickerSpark's AI analysis on ADIL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.26M
- P/E
- -0.20
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 3150.23
- EV/EBITDA
- -0.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 1642.31%
- ROIC
- -363111.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,799,462
- Net Income
- $-7,977,171+39.6%
- EPS
- $-11.93+32.8%
- OCF Growth
- +6.2%
- FCF Growth
- +6.2%
- 52W High
- $8.75
- 52W Low
- $1.31
- 50D MA
- $4.64
- 200D MA
- $3.13
- Beta
- 1.50
- RSI (14)
- 49
- Avg Volume
- 56.77K
No earnings-call transcripts are available for ADIL yet.
- Free Float
- 80.4%
- Shares Outstanding
- 2.63M
- Float Shares
- 2.11M
of shares held by institutions
18 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 156.02K | 0 |
| Jane Street Group, LLC | 53.95K | ▲ 21.83K |
| Citadel Advisors LLC | 29.55K | ▲ 29.55K |
| Geode Capital Management, LLC | 21.55K | ▲ 9.15K |
| Vanguard Fiduciary Trust Co | 15.88K | ▲ 10.00K |
| China Universal Asset Management Co., Ltd. | 12.80K | ▲ 4.80K |
| Vanguard Capital Management LLC | 10.41K | ▲ 4.58K |
| Ubs Group AG | 1.69K | ▼ 17.46K |
| Tower Research Capital LLC (Trc) | 1.42K | ▲ 63 |
| Barclays PLC | 1.09K | ▲ 1.09K |
| Blackrock, Inc. | 304 | 0 |
| Raffa Wealth Management, LLC | 83 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 28, 26 | Davidson Matt | other | 333,830 |
| Oct 28, 26 | Davidson Matt | other | 232,417 |
| Oct 28, 26 | Davidson Matt | other | 286,044 |
| Oct 28, 26 | Davidson Matt | other | 232,417 |
| Oct 28, 26 | Davidson Matt | other | 31,914 |
| Oct 28, 26 | Davidson Matt | other | 1,822.13 |
| Oct 28, 26 | Davidson Matt | other | 101.298 |
| Oct 28, 26 | Saiki Julie | other | 0 |
| Oct 28, 26 | Saiki Julie | other | 0 |
| Oct 28, 26 | Saiki Julie | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ADIL coverage
Recent articles, reports, and earnings notes.
No research on ADIL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADIL report →Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 19
Azora Therapeutics Reports 2026 Third Quarter Financial Results and Provides Business Update
globenewswire.com · Nov 12
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
globenewswire.com · Oct 28
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
globenewswire.com · Oct 26
Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis
globenewswire.com · Oct 16
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Sep 30
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 25
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
globenewswire.com · Aug 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.